For example, HER2/neu-targeted mRNA vaccines delivered in LNPs also demonstrated promising immunogenicity and tumor reduction in pre-clinical models of breast cancer HER2+ (Tapescu et al., 2024). The gene discussed is ERBB2; the disease is neoplasm.